Recording and Q&A from webinar 'Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders'
Recording and Q&A from webinar 'Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders'
With enthusiastic engagement from staff, we’ve cultivated a robust H&S culture, ensuring we continuously prioritize the health, safety, and well-being of everyone at Metrion.
IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.
IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.
'Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics) receives ‘2024 Technology Innovation Publication Award’.
I am currently studying Biomedical Sciences at the University of Manchester. Through my previous years of education, I enjoyed studying biology and engaging in practical experiments, particularly those with clinical relevance, which ultimately guided my degree selection.
My 12 month industrial placement at Metrion Biosciences was a truly remarkable experience that has helped me grow both personally and professionally. Choosing to complete a placement year was a big decision for me which was made 100% worth it!
Two-pore domain K+ (K2P) channels are a family of four-pass transmembrane K+ channels that dimerise, as homomers or heteromers, to form a functional K+ channel complex capable of regulating membrane potential through a background K+ conductance.
Kv3.1 is a voltage-gated potassium channel encoded by the KCNC1 gene. At the recent SLAS EU meeting, we presented a poster to demonstrate how a cell line expressing the KCNC1 V434L mutation was generated and validated using biophysical and pharmacological methods, then used to screen approximately 6,800 compounds from The Broad Institute Repurposing Hub to identify inhibitors for potential use in the treatment of patients with this rare mutation.